Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Partners with Atascosa Explor

18 Jun 2008 07:00

RNS Number : 9543W
ViaLogy PLC
18 June 2008
 



ViaLogy partners with Texas exploration group Atascosa to analyse onshore oil fields

Pasadena, 18 June:  ViaLogy PLC (LSE:VIY)a leading innovator of real-time network-centric signal processing platforms, announces that it has entered into an agreement with a Texas-based oil and gas exploration and production company, Atascosa Exploration LLC,  of San Antonio, to use ViaLogy's  unique technology, QuantumRD™, to analyse seismic data for more accurate definition of the extent and density of underground oil reservoirs prior to the commencement of drilling. The data analysis on three prospective Texas-based well sites will begin immediately. Complete results will be delivered by ViaLogy to Atascosa within three weeks, and exploratory drillinto prove the technology will commence soon afterwards.

The problems of predicting oil traps from coarse seismic data analysis have plagued the oil and gas industry for decades. Pinpoint accuracy is essentialPredictions that are just a few feet out can waste millions of dollars.

QuantumRD applies ViaLogy's patented and proven Quantum Resonance Interferometry (QRI™) technology to analyse coarse 2D and 3D seismic signals and extract more detailed and accurate information than has hitherto been possibleFor the first three pilot wells ViaLogy and Atascosa have reached a non-operating interest participation arrangement, which is based on production in excess of their oil trap estimates prior to the QuantumRD analysis. Assuming that the analysis proves successful the two companies have agreed to form a joint venture company or other business arrangement for the commercialisation of Quantum RD within the United States.

Atascosa CEO, John D. Mullins, said, "We are delighted that Atascosa can take the lead in bringing ViaLogy's technology to market. A successful pilot should result in the widespread use of QuantumRD throughout the industry."

 ViaLogy CEO, Robert W. Dean, said, "QuantumRD should increase the accuracy of existing and future seismic petroleum data reduce false positives about where to drill, and have a significant impact on the oil exploration industry. It should also offer ViaLogy opportunity to expand its sales in an adjacent market. Atascosa is the ideal partner for us."

Mr. Dean pointed out that, if the pilot analysis proves successful, the potential for QuantumRD™ iextensive According to Energy Information Administration (EIA)'s 2006 Annual Report, US had over 21 billion barrels of proven oil reserves. Most of the newer discoveries are in smaller fields. However, the number of newer oilfield discoveries has declined from 1400 in 2001 to 30 by 2006Just over 40 new reservoirs were discovered in known US fields in 2006 based on EIA released numbers.

"Due to the high cost of oil today, producers can now afford to bring on line reserves that were previously passed over because of production rate or quantity or quality of reservoir. QuantumRD shines in this environment because it allows a clear definition of reservoir size and shape. Based on EIA released data, wells in the US are now averaging over 5700 feet in depth. As the cost to drill wells between 5,000 and 12,000 feet is now approximately $1.5 million to $4 million dollars, making an accurate prediction of reservoir characteristics is even more of an economic necessity. ViaLogy's preferred business model is ainterpretation fee and overriding royalty interest (ORRI).  Our ability to accurately predict reservoir size and quality should become a required part of the search for hydrocarbons here and abroad."

  For Further Information please contact

ViaLogy

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 

Atascosa Exploration LLC

John D. Mullins, CEO (+1 210-402-3656).

Nominated Advisor (Seymour Pierce)

Mark Percy +44 (0) 20-7107-8000 

PR Consultants - Redleaf Communications

Samantha Robbins / Anna Dunkin +44 (0) 20-7822-0200

 

About ViaLogy: Network Centric Signal Processing.

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. Vialogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.vialogy.com. 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRFDLLFVQBXBBD
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.